The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
Advised Hitachi, a leading global industrial conglomerate, on the sale of its LiB business including Hitachi Vehicle Energy
Advised ADEKA Corporation, a global chemical manufacturer, on the acquisition of 51% stake of Nihon Nohyaku via the combination of the Tender Offer and Capital Injection
Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.
Advised Osaka Gas, a Japanese utility, on the acquisition of 35% of Sabine Oil & Gas’s interest in oil and gas properties located primarily in Harrison and Panola Counties, Texas
Advised PERSOL HOLDINGS, one of Japan’s largest HR service companies, on its acquisition of ASX-listed Programmed Maintenance Services, a leading Australian and New Zealand based provider of staffing and maintenance services
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
Advised Sato Holdings Corporation, a leading global provider of Auto-ID solutions, on its acquisition of a significant minority stake in DataLase Ltd, a UK-based provider of materials for laser coding and marking of products and packaging
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
Advised Hitachi, LTD / Hitachi Appliances, Inc, a leading global industrial conglomerate focused on information and telecommunications systems, power systems and social systems, on their formation of a global HVAC joint venture with Johnson Controls
Advised NYK Ports LLC, a leading port operating and stevedoring company, on the sale of a 49% stake to Macquarie Infrastructure Partners, a leading Australian infrastructure fund
Advised Goodman Fielder, a leading Australian listed food company, on the sale of its New Zealand flour milling business, Champion Flour, to Nisshin Seifun Group Inc.
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
Advised Wacker Chemie AG on the sale of Wacker Chemical Corporation’s 50% equity stake in Planar Solutions LLC, a dedicated CMP slurry manufacturer, to its JV partner, FUJIFILM Corporation
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company